| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8744950 | Clinical Microbiology and Infection | 2018 | 70 Pages |
Abstract
Preventive strategies are particularly encouraged to minimize the occurrence of neisserial infection associated with eculizumab.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Microbiology
![ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli](/preview/png/8744950.png "First Page Preview: ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli")
Authors
K.L. Winthrop, X. Mariette, J.T. Silva, E. Benamu, L.H. Calabrese, A. Dumusc, J.S. Smolen, J.M. Aguado, M. Fernández-Ruiz,